HORIZANT 600 mg
Sponsors
XenoPort, Inc.
Conditions
RLS
Phase 4
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
NCT02560766
Start: 2016-02-29End: 2023-10-31Target: 132Updated: 2021-06-09
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
NCT02633683
Start: 2016-01-31End: 2024-07-31Target: 144Updated: 2021-06-09